FibroBiologics, Inc. 8-K

What Happened
FibroBiologics, Inc. (FBLG) announced on May 1, 2026 that it entered into an At‑The‑Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC under which the company may sell up to $6,150,000 of its common stock from time to time. Sales, if any, will be made into the market pursuant to the company’s shelf registration (Form S‑3, Reg. No. 333‑284663, declared effective Feb. 10, 2025) and an ATM prospectus supplement; the company is not obligated to sell any shares.

Key Details

• Agreement date: May 1, 2026; Sales agent: H.C. Wainwright & Co., LLC.
• Maximum aggregate offering amount: $6,150,000 (via an at‑the‑market program).
• Fees and expenses: 3.0% of gross proceeds payable to the sales agent; $100,000 reimbursement for Wainwright’s counsel fees, plus up to $5,000 per due diligence update for Form 10‑K or material amendments and $3,500 per due diligence update for Form 10‑Q.
• Other terms: Company may also sell shares to the agent as principal; customary indemnification and contribution provisions included; offering ends when the $6.15M is sold or the Sales Agreement is terminated.

Why It Matters
This ATM provides FibroBiologics with an on‑going, flexible way to raise equity capital for working capital and general corporate purposes without a single large offering. For investors, an ATM can dilute existing shareholders over time if shares are sold, and the timing, amount and price of any sales are uncertain—there is no guarantee the company will sell any shares under the agreement. The agreement’s costs (3% placement fee plus specified legal/due‑diligence reimbursements) are fixed terms to consider when evaluating potential capital raises.